Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

New England Journal of Medicine

Volumn 353, Issue 13, 2005, Pages 1332-1341

  Abraham, Edward ^a   Laterre, Pierre François ^b   Garg, Rekha ^c   Levy, Howard ^c   Talwar, Deepak ^d   Trzaskoma, Benjamin L ^c   François, Bruno ^e   Guy, Jeffrey S ^f   Brückmann, Martina ^g   Rea Neto, Álvaro ^h   Rossaint, Rolf ⁱ   Perrotin, Dominique ^j   Sablotzki, Armin ^k   Arkins, Nancy ^c   Utterback, Barbara G ^c   Macias, William L ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c ELI LILLY AND COMPANY   (United States)

^d Metro Hospital and Heart Institute   (India)

^e DUPUYTREN UNIVERSITY HOSPITAL   (France)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

ⁱ UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^j CHU BRETONNEAU   (France)

^k MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; PLACEBO;

AGED; ARTICLE; BLEEDING; BODY WEIGHT; BRAIN HEMORRHAGE; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG INFUSION; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGIC SHOCK; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SEPSIS; STATISTICAL SIGNIFICANCE;

EID: 25444492831     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa050935     Document Type: Article

References (19)

1. Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: sampling, selection, and society. Crit Care 2004;8:222-6.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
3. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units. JAMA 1995;274:968-74.
4. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002;28:108-21. [Erratum, Intensive Care Med 2002;28:525-6.]
5. Brun-Buisson C, Meshaka P, Pinton P, Vallet B, EPISEPSIS Study Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004;30:580-8.
6. Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997;278:234-40.
7. Silva E, de Almeida PM, Sogayar AC, et al. Brazilian Sepsis Epidemiological Study (BASES study). Crit Care 2004;8:R251-R260.
8. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003;312:332-8.
9. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004;30:589-96. [Erratum, Intensive Care Med 2004;30:1252.]
10. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
11. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003;31:12-9.
12. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
13. DeMets DL, Fleming TR, Whitley RJ, et al. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials. Control Clin Trials 1995;16:408-21.
14. Angus DC, Laterre PF, Helterbrand J, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004;32:2199-206.
15. Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med 2002;347:1030-4.
16. Macias WL, Vallet B, Bernard GR, et al. Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med 2004;32:2385-91.
17. Dhainaut JF, Yan SB, Margolis BD, et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003;90:642-53.
18. Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003;7:155-63.
19. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med (in press).